Skip To Content
JEWISH. INDEPENDENT. NONPROFIT.
Breaking News

Medical Marijuana a Success in Israel

More than two-thirds of cancer patients who were prescribed medical marijuana to combat pain are reportedly satisfied with the treatment, according to a comprehensive study conducted for the first time in Israel.

The study – conducted recently at Sheba Medical Center, Tel Hashomer, in conjunction with the Israel Cancer Association – involved 264 cancer patients who were treated with medical marijuana for a full year.

Some 61 percent of the respondents reported a significant improvement in their quality of life as a result of the medical marijuana, while 56 percent noted an improvement in their ability to manage pain. In general, 67 percent were in favor of the treatment, while 65 percent said they would recommend it to other patients.

The findings were presented earlier this month at an Israeli Oncologists Union conference in Eilat. The study was led by Dr. Ido Wolf, the director of oncology at the Sheba Cancer Center, with the assistance of researchers Yasmin Leshem, Damien Urbach, Adato Berliz, Tamar Ben Ephraim and Meital Gerty.

According to the study, the most common types of cancer for which medical marijuana is prescribed are lung cancer (21 percent ), breast cancer (12 percent ) and pancreatic cancer (10 percent ).

Researchers found that an average of 325 days passed between the time that patients were diagnosed with cancer and the time that they submitted permit requests to grow or possess medical marijuana. About 81 percent of those requests cited pain resulting from the illness. Some 8 percent of patients requested medical marijuana to combat nausea, while another 8 percent complained of weakness.

For more, go to Haaretz.com

A message from our CEO & publisher Rachel Fishman Feddersen

I hope you appreciated this article. Before you go, I’d like to ask you to please support the Forward’s award-winning, nonprofit journalism during this critical time.

We’ve set a goal to raise $260,000 by December 31. That’s an ambitious goal, but one that will give us the resources we need to invest in the high quality news, opinion, analysis and cultural coverage that isn’t available anywhere else.

If you feel inspired to make an impact, now is the time to give something back. Join us as a member at your most generous level.

—  Rachel Fishman Feddersen, Publisher and CEO

With your support, we’ll be ready for whatever 2025 brings.

Republish This Story

Please read before republishing

We’re happy to make this story available to republish for free, unless it originated with JTA, Haaretz or another publication (as indicated on the article) and as long as you follow our guidelines. You must credit the Forward, retain our pixel and preserve our canonical link in Google search.  See our full guidelines for more information, and this guide for detail about canonical URLs.

To republish, copy the HTML by clicking on the yellow button to the right; it includes our tracking pixel, all paragraph styles and hyperlinks, the author byline and credit to the Forward. It does not include images; to avoid copyright violations, you must add them manually, following our guidelines. Please email us at [email protected], subject line “republish,” with any questions or to let us know what stories you’re picking up.

We don't support Internet Explorer

Please use Chrome, Safari, Firefox, or Edge to view this site.